Resetting cancer stem cell regulatory nodes upon MYC inhibition

EMBO Reports

Volumn 17, Issue 12, 2016, Pages 1872-1889

  Galardi, Silvia ^a   Savino, Mauro ^b   Scagnoli, Fiorella ^b   Pellegatta, Serena ^c,d   Pisati, Federica ^e   Zambelli, Federico ^f,g   Illi, Barbara ^b   Annibali, Daniela ^b   Beji, Sara ^b   Orecchini, Elisa ^a   Alberelli, Maria Adele ^b   Apicella, Clara ^b   Fontanella, Rosaria Anna ^b   Michienzi, Alessandro ^a   Finocchiaro, Gaetano ^c   Farace, Maria Giulia ^a   Pavesi, Giulio ^g   Ciafrè, Silvia Anna ^a   Nasi, Sergio ^b,h  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Istituto Di Biologia E Patologia Molecolari Rome   (Italy)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^f CNR   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

gene networks; glioblastoma stem cells; MYC inhibition

Indexed keywords

MICRORNA; MYC PROTEIN; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; POU3F2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTOME; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ID4 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION PROTEIN; NERVE PROTEIN; OLIG2 PROTEIN, HUMAN; OMOMYC PROTEIN; PEPTIDE FRAGMENT; PROTEIN BINDING; TRANSCRIPTION FACTOR ZEB1; ZEB1 PROTEIN, HUMAN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CELL POPULATION; CONTROLLED STUDY; FEMALE; GENOME; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STEM CELL SELF-RENEWAL; TUMOR DIFFERENTIATION; TUMOR ENGRAFTMENT; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; WESTERN BLOTTING; APOPTOSIS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENETICS; ONCOGENE MYC; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; GLIOBLASTOMA; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEINS; MICRORNAS; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TUMOR MICROENVIRONMENT; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 84999740010     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201541489     Document Type: Article

References (70)

1. Gabay M, Li Y, Felsher DW (2014) MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 4: a014241
2. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, Cantor AB, Orkin SH (2010) A MYC network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 143: 313–324
3. Conacci-Sorrell M, McFerrin L, Eisenman RN (2014) An overview of MYC and its interactome. Cold Spring Harb Perspect 4: a014357
4. Rahl P, Young RA (2014) MYC and transcription elongation. Cold Spring Harb Perspect Med 4: a020990
5. Wolf E, Lin CY, Eilers M, Levens D (2015) Taming of the beast: shaping MYC-dependent amplification. Trends Cell Biol 25: 241–248
6. O'Donnell KA, Wentzel EA, Zeller K, Dang CV, Mendell JT (2005) c-MYC-regulated microRNAs modulate E2F1 expression. Nature 435: 839–843
7. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ et al (2005) A microRNA polycistron as a potential human oncogene. Nature 435: 828–833
8. Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R, Zhang Y, Chan JC, Fu K, Marquez VE et al (2012) Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 22: 506–523
9. Li Y, Choi PS, Casey SC, Dill DL, Felsher DW (2014) MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 26: 262–272
10. Nie Z, Hu G, Wei G, Cui K, Yamane A, Resch W, Wang R, Green DR, Tessarollo L, Casellas R et al (2012) c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell 151: 68–79
11. Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI, Young RA (2012) Transcriptional amplification in tumor cells with elevated c-MYC. Cell 51: 56–67
12. Sabò A, Kress TR, Pelizzola M, de Pretis S, Gorski MM, Tesi A, Morelli MJ, Bora P, Doni M, Verrecchia A et al (2014) Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis. Nature 511: 488–492
13. Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M et al (2014) Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. Nature 511: 483–487
14. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM et al (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478: 529–533
15. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J et al (2011) BET bromodomain inhibition as a therapeutic strategy to target c-MYC. Cell 146: 904–917
16. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M et al (2011) RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524–528
17. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S (1998) Design and properties of a MYC derivative that efficiently homodimerizes. Oncogene 17: 2463–2472
18. Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S (2002) Omomyc, a potential MYC dominant negative, enhances MYC-induced apoptosis. Cancer Res 62: 3507–3510
19. Soucek L, Nasi S, Evan GI (2004) Omomyc expression in skin prevents MYC-induced papillomatosis. Cell Death Differ 11: 1038–1045
20. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI (2008) Modelling MYC inhibition as a cancer therapy. Nature 455: 679–683
21. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, Soucek L, Nasi S (2011) The action mechanism of the MYC inhibitor termed Omomyc may give clues on how to target MYC for cancer therapy. PLoS One 6: e22284
22. Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L (2011) Endogenous MYC maintains the tumor microenvironment. Genes Dev 25: 907–916
23. Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzàlez-Juncà A, Sodir NM et al (2014) MYC inhibition is effective against glioma and reveals a role for MYC in proficient mitosis. Nat Commun 5: 4632
24. Jansen M, Yip S, Louis DN (2010) Molecular pathology in adult gliomas: diagnostic, prognostic, and predictive markers. Lancet 9: 717–726
25. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391–403
26. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760
27. Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN (2008) c-MYC is required for maintenance of glioma cancer stem cells. PLoS One 3: e3769
28. De Bacco F, Casanova E, Medico E, Pellegatta S, Orzan F, Albano R, Luraghi P, Reato G, D'Ambrosio A, Porrati P et al (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72: 4537–4550
29. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G (2009) SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells 27: 40–48
30. Wang J, Wang Q, Cui Y, Liu ZY, Zhao W, Wang CL, Dong Y, Hou L, Hu G, Luo C et al (2012) Knockdown of cyclin D1 inhibits proliferation, induces apoptosis, and attenuates the invasive capacity of human glioblastoma cells. J Neurooncol 106: 473–484
31. Piccin D, Yu F, Morshead CM (2013) Notch signaling imparts and preserves neural stem characteristics in the adult brain. Stem Cells Dev 22: 1541–1550
32. Matsuda Y, Ishiwata T, Yoshimura H, Hagio M, Arai T (2015) Inhibition of nestin suppresses stem cell phenotype of glioblastomas through the alteration of post-translational modification of heat shock protein HSPA8/HSC71. Cancer Lett 357: 602–611
33. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z et al (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455: 1129–1133
34. Chen J, Li Y, Yu TS, McKay RM, Burns DK, Kernie SG, Parada LF (2012) A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488: 522–526
35. Daniel P, Filiz G, Brown DV, Hollande F, Gonzales M, D'Abaco G, Papalexis N, Phillips WA, Malaterre J, Ramsay RG et al (2014) Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. Oncogenesis 3: e108
36. Bellail AC, Olson JJ, Hao C (2014) SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun 5: 4234
37. Goldshmit Y, Trangle SS, Kloog Y, Pinkas-Kramarski R (2014) Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma. Oncotarget 5: 8602–8613
38. Aprea J, Prenninger S, Dori M, Ghosh T, Monasor LS, Wessendorf E, Zocher S, Massalini S, Alexopoulou D, Lesche M et al (2013) Transcriptome sequencing during mouse brain development identifies long non-coding RNAs functionally involved in neurogenic commitment. EMBO J 32: 3145–3160
39. Prabhakar S, Asuthkar S, Lee W, Chigurupati S, Zakharian E, Tsung AJ, Velpula KK (2014) Targeting DUSPs in glioblastomas - wielding a double-edged sword? Cell Biol Int 38: 145–153
40. Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV et al (2014) Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 157: 580–594
41. Yang P, Wang Y, Che J, Li H, Kang L, Zhang Y, Chen S, Zhu B, Gao S (2011) RCOR2 is a subunit of the LSD1 complex that regulates ESC property and substitutes for SOX2 in reprogramming somatic cells to pluripotency. Stem Cells 29: 791–801
42. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98–110
43. Jackstadt R, Hermeking H (2015) MicroRNAs as regulators and mediators of c-MYC function. Biochim Biophys Acta 1849: 544–553
44. Karsy M, Arslan E, Moy F (2013) Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme. Genes Cancer 3: 3–15
45. Psathas JN, Thomas-Tikhonenko A (2014) MYC and the art of MicroRNA maintenance. Cold Spring Harb Perspect Med 4: a014175
46. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT et al (2009) c-MYC suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458: 62–65
47. Lovat F, Fassan M, Gasparini P, Rizzotto L, Cascione L, Pizzi M, Vicentini C, Balatti V, Palmieri D, Costinean S et al (2015) miR-15b/16-2 deletion promotes B-cell malignancies. Proc Natl Acad Sci USA 112: 11636–11641
48. Vlachos IS, Kostoulas N, Vergoulis T, Georgakilas G, Reczko M, Maragkakis M, Paraskevopoulou MD, Prionidis K, Dalamagas T, Hatzigeorgiou AG (2012) DIANA miRPath v. 2.0: investigating the combinatorial effect of microRNAs in pathways. Nucleic Acids Res 40: W498–W504
49. Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN et al (2013) An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep 3: 1567–1579
50. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2013) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593–601
51. Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, Kupper MD, Neal D et al (2012) The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance. EMBO Mol Med 5: 1196–1212
52. Katakowski M, Zheng X, Jiang F, Rogers T, Szalad A, Chopp M (2010) MiR-146b-5p suppresses EGFR expression and reduces in vitro migration and invasion of glioma. Cancer Invest 28: 1024–1030
53. Carroll PA, Diolaiti D, McFerrin L, Gu H, Djukovic D, Du J, Cheng PF, Anderson S, Ulrich M, Hurley JB et al (2015) Deregulated MYC requires MondoA/Mlx for metabolic reprogramming and tumorigenesis. Cancer Cell 27: 271–285
54. Levens D (2013) Cellular MYCro economics: balancing MYC function with MYC expression. Cold Spring Harb Perspect Med 3: a022483
55. Dang CV (2013) MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harb Perspect Med 3: a014217
56. Mongiardi MP, Savino M, Bartoli L, Beji S, Nanni S, Scagnoli F, Falchetti ML, Favia A, Farsetti A, Levi A et al (2015) Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells. Sci Rep 5: 15494
57. Joseph JV, Conroy S, Tomar T, Eggens-Meijer E, Bhat K, Copray S, Walenkamp AM, Boddeke E, Balasubramanyian V, Wagemakers M et al (2014) TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion. Cell Death Dis 5: e1443
58. Hnisz D, Schuijers J, Lin CY, Weintraub AS, Abraham BJ, Lee TI, Bradner JE, Young RA (2015) Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol Cell 58: 362–370
59. Dowen JM, Fan ZP, Hnisz D, Ren G, Abraham BJ, Zhang LN, Weintraub AS, Schuijers J, Lee TI, Zhao K et al (2014) Control of cell identity genes occurs in insulated neighbourhoods in mammalian chromosomes. Cell 159: 74–87
60. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafrè SA, Farace MG (2007) miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 282: 23716–23724
61. Orecchini E, Doria M, Michienzi A, Giuliani E, Vassena L, Ciafrè SA, Farace MG, Galardi S (2014) The HIV-1 Tat protein modulates CD4 expression in human T cells through the induction of miR-222. RNA Biol 11: 334–338
62. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10: R25
63. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum C, Myers RM, Brown M, Li W et al (2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol 9: R137
64. Zambelli F, Pesole G, Pavesi G (2013) PscanChIP: finding over-represented transcription factor-binding site motifs and their correlations in sequences from ChIP-Seq experiments. Nucleic Acids Res 41: W535–W543
65. D'Antonio M, D'Onorio De Meo P, Pallocca M, Picardi E, D'Erchia AM, Calogero RA, Castrignanò T, Pesole G (2015) RAP: RNA-Seq Analysis Pipeline, a new cloud-based NGS web application. BMC Genom 16: S3
66. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV (2003) An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 4: R69
67. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499–507
68. Schlosser I, Hölzel M, Hoffmann R, Burtscher H, Kohlhuber F, Schuhmacher M, Chapman R, Weidle UH, Eick D (2005) Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene 24: 520–524
69. Schuhmacher M, Kohlhuber F, Hölzel M, Kaiser C, Burtscher H, Jarsch M, Bornkamm GW, Laux G, Polack A, Weidle UH et al (2001) The transcriptional program of a human B cell line in response to Myc. Nucleic Acids Res 29: 397–406
70. Cowling VH, Cole MD (2008) An N-Myc truncation analogous to c-Myc-S induces cell proliferation independently of transactivation but dependent on Myc homology box II. Oncogene 27: 1327–1332